Reports Q4 revenue $38.8M, consensus $37.2M. "In 2022, we delivered strong year-over-year growth in revenue and test report volume, reflecting solid execution by our Castle team," said Derek Maetzold, CEO. "Further, we believe our success continues to lay the foundation for future growth in 2023 and beyond. We are pleased to provide our financial outlook for 2023, expecting between $170-180 million in total revenue. We expect continued progress on our growth initiatives in 2023, including expanded evidence development supporting our proprietary commercial and pipeline tests and the continued integrations of our acquired franchises–gastroenterology and mental health–which we expect to contribute to achieving our 2025 financial targets of total revenue between $255-330 million and net operating cash flow positivity."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CSTL:
- Castle Biosciences management to meet virtually with Stephens
- Castle up 1.5% after announcing presentation for dermatology conference
- Castle to share data on clinical value skin cancer test at Hawaii conference
- Castle Biosciences expects to meet or exceed guided FY22 revenue of $132M-$137M
- Castle Biosciences initiated with an Outperform, $54 target at Scotiabank
